Sector Gamma As
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 11, 2025), Sector Gamma As reported 30 stock positions worth $290.9 million. Its top holding was Pfizer (PFE) at 10.5% of the portfolio, followed by Medtronic (MDT, 8.8%) and Bristol-Myers Squibb (BMY, 7.1%). Compared with Q3 2024, it opened 4 new positions, sold out of 3, added to 8 and reduced 15. The biggest buy was a new position in Johnson & Johnson (JNJ) and the biggest sale Baxter International (BAX, shares −59%).
- Most Recent 13F
- Q2 2026
- Location
- OSLO, Q8
- CIK
- 0001475373
- Portfolio Value
- $290.9M (Q4 2024)
- SEC Filing
- 0000945621-25-000153 ↗ filed Feb 11, 2025
Holdings Value
Holdings 30 stocks · $290.9M
| PFE Pfizer Inc. | 10.53% | 1,155,000 | $30.6M | Add +40.9% |
| MDT Medtronic PLC | 8.79% | 320,000 | $25.6M | Reduce -4.5% |
| BMY Bristol-Myers Squibb Co. | 7.12% | 366,166 | $20.7M | Reduce -39.2% |
| GILD Gilead Sciences Inc. | 6.27% | 197,500 | $18.2M | Reduce -31.7% |
| BDX Becton Dickinson and Co. | 5.93% | 76,000 | $17.2M | Reduce -1.7% |
| ZBH Zimmer Biomet Holdings Inc. | 5.00% | 137,714 | $14.5M | Add +29.9% |
| BMRN Biomarin Pharmaceutical Inc. | 4.91% | 217,348 | $14.3M | Add +14.2% |
| INCY Incyte Corp. | 4.69% | 197,400 | $13.6M | Reduce -23.8% |
| AMGN Amgen Inc. | 4.12% | 46,000 | $12.0M | Add +187.5% |
| JNJ Johnson & Johnson | 3.88% | 78,000 | $11.3M | New |
| CAH Cardinal Health Inc. | 3.58% | 88,000 | $10.4M | Reduce -24.9% |
| CNC Centene Corp. | 3.54% | 170,000 | $10.3M | Add +79.0% |
| CVS CVS Health Corp. | 3.35% | 217,000 | $9.7M | Reduce -28.1% |
| BRKR Bruker Corp. | 3.20% | 158,970 | $9.3M | No change |
| QGEN Qiagen NV | 3.12% | 203,993 | $9.1M | Reduce -8.6% |
| IONS Ionis Pharmaceuticals Inc. | 2.83% | 235,842 | $8.2M | Add +11.9% |
| EW Edwards Lifesciences Corp. | 2.52% | 99,000 | $7.3M | Reduce -6.7% |
| ELV Elevance Health Inc. | 2.19% | 17,279 | $6.4M | Reduce -34.3% |
| BIO Bio-Rad Laboratories-A | 1.90% | 16,829 | $5.5M | No change |
| BAX Baxter International Inc. | 1.59% | 158,650 | $4.6M | Reduce -58.8% |
| BNTX Biontech SE-ADR | 1.57% | 40,000 | $4.6M | No change |
| BIIB Biogen Inc. | 1.52% | 29,000 | $4.4M | Reduce -17.5% |
| GEHC GE Healthcare Technology | 1.34% | 50,000 | $3.9M | Reduce -53.1% |
| HUM Humana Inc. | 1.22% | 14,000 | $3.6M | Add +16.7% |
| ELAN Elanco Animal Health Inc. | 1.15% | 276,907 | $3.4M | New |
| PTCT PTC Therapeutics Inc. | 1.01% | 65,250 | $2.9M | New |
| THC Tenet Healthcare Corp. | 0.95% | 22,000 | $2.8M | Reduce -16.5% |
| TANDEM DIABETES CARE INC (TNDM 1.5 05/01/25) | 0.82% | 66,023 | $2.4M | New |
| LNTH Lantheus Holdings Inc. | 0.79% | 25,712 | $2.3M | Reduce -18.9% |
| LEGN Legend Biotech Corp.-ADR | 0.54% | 48,495 | $1.6M | Add +25.1% |
Portfolio Sells Q3 2024 → Q4 2024
| BAX Baxter International Inc. | Reduce -58.8% | 1.59% | −2.85 |
| CVS CVS Health Corp. | Reduce -28.1% | 3.35% | −2.41 |
| BMY Bristol-Myers Squibb Co. | Reduce -39.2% | 7.12% | −2.33 |
| ELV Elevance Health Inc. | Reduce -34.3% | 2.19% | −1.95 |
| GEHC GE Healthcare Technology | Reduce -53.1% | 1.34% | −1.69 |
| UHS Universal Health Services-B | Sold out | 0.00% | −1.22 |
| GILD Gilead Sciences Inc. | Reduce -31.7% | 6.27% | −1.08 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.92 |
| ALKS Alkermes PLC | Sold out | 0.00% | −0.85 |
| BIIB Biogen Inc. | Reduce -17.5% | 1.52% | −0.54 |
| INCY Incyte Corp. | Reduce -23.8% | 4.69% | −0.51 |
| THC Tenet Healthcare Corp. | Reduce -16.5% | 0.95% | −0.37 |
| MDT Medtronic PLC | Reduce -4.5% | 8.79% | −0.36 |
| CAH Cardinal Health Inc. | Reduce -24.9% | 3.58% | −0.35 |
| LNTH Lantheus Holdings Inc. | Reduce -18.9% | 0.79% | −0.27 |
| QGEN Qiagen NV | Reduce -8.6% | 3.12% | +0.04 |
| BDX Becton Dickinson and Co. | Reduce -1.7% | 5.93% | +0.27 |
| EW Edwards Lifesciences Corp. | Reduce -6.7% | 2.52% | +0.39 |
Portfolio Buys Q3 2024 → Q4 2024
| JNJ Johnson & Johnson | New | 3.88% | +3.88 |
| PFE Pfizer Inc. | Add +40.9% | 10.53% | +3.33 |
| AMGN Amgen Inc. | Add +187.5% | 4.12% | +2.56 |
| ZBH Zimmer Biomet Holdings Inc. | Add +29.9% | 5.00% | +1.53 |
| CNC Centene Corp. | Add +79.0% | 3.54% | +1.37 |
| ELAN Elanco Animal Health Inc. | New | 1.15% | +1.15 |
| PTCT PTC Therapeutics Inc. | New | 1.01% | +1.01 |
| BMRN Biomarin Pharmaceutical Inc. | Add +14.2% | 4.91% | +0.85 |
| TANDEM DIABETES CARE INC (TNDM 1.5 05/01/25) | New | 0.82% | +0.82 |
| IONS Ionis Pharmaceuticals Inc. | Add +11.9% | 2.83% | +0.27 |
| HUM Humana Inc. | Add +16.7% | 1.22% | +0.07 |
| LEGN Legend Biotech Corp.-ADR | Add +25.1% | 0.54% | −0.03 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 40 | $461.0M | BMY, MRK, MDT, PFE, INCY |
| Q1 2026 | 42 | $423.5M | BMY, MRK, PFE, MDT, INCY |
| Q4 2025 | 36 | $438.7M | BMY, MRK, MDT, BDX, GILD |
| Q3 2025 | 41 | $403.3M | PFE, MDT, MRK, BMY, BDX |
| Q2 2025 | 38 | $305.9M | PFE, MDT, BMY, BDX, MRK |
| Q1 2025 | 33 | $312.2M | BMY, PFE, BDX, MDT, AMGN |
| Q4 2024 | 30 | $290.9M | PFE, MDT, BMY, GILD, BDX |
| Q3 2024 | 29 | $329.6M | BMY, MDT, GILD, PFE, CVS |
| Q2 2024 | 28 | $267.7M | GILD, PFE, BMY, MDT, ELV |
| Q1 2024 | 28 | $354.8M | MDT, PFE, BMY, CVS, CAH |